Michael Phillips, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Does long-term treatment with danazol really benefit patients with autoimmune thrombocytopenia? Unfortunately, Dr. Ahn and colleagues (1) have not answered this question convincingly because their study did not incorporate controls who were not treated with danazol. The improved platelet counts observed in this uncontrolled "before and after" experiment could possibly have been due to factors other than danazol alone, for example, spontaneous improvement, placebo response, potentiation of the effects of glucocorticoids, or a combination of these effects.
A study incorporating a placebo control group would answer these objections and would also be completely ethical because all subjects
Phillips M. Danazol and Idiopathic Thrombocytopenic Purpura. Ann Intern Med. 1990;112:474–475. doi: https://doi.org/10.7326/0003-4819-76-3-112-6-474
Download citation file:
Published: Ann Intern Med. 1990;112(6):474-475.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use